5244702025-10-012025-12-315244702025-12-315244702025-04-012025-12-315244702025-10-012025-12-31in-capmkt:OtherExpenses1Member5244702025-04-012025-12-31in-capmkt:OtherExpenses1Member5244702025-10-012025-12-31in-capmkt:ReportableSegments1Member5244702025-10-012025-12-31in-capmkt:ReportableSegments2Member5244702025-10-012025-12-31in-capmkt:ReportableSegments3Member5244702025-04-012025-12-31in-capmkt:ReportableSegments1Member5244702025-04-012025-12-31in-capmkt:ReportableSegments2Member5244702025-04-012025-12-31in-capmkt:ReportableSegments3Member5244702025-10-012025-12-31in-capmkt:ReportableSegments1Member5244702025-10-012025-12-31in-capmkt:ReportableSegments2Member5244702025-10-012025-12-31in-capmkt:ReportableSegments3Member5244702025-04-012025-12-31in-capmkt:ReportableSegments1Member5244702025-04-012025-12-31in-capmkt:ReportableSegments2Member5244702025-04-012025-12-31in-capmkt:ReportableSegments3Member5244702025-10-012025-12-31in-capmkt:ReportableSegments1Member5244702025-12-31in-capmkt:ReportableSegments1Member5244702025-10-012025-12-31in-capmkt:ReportableSegments2Member5244702025-12-31in-capmkt:ReportableSegments2Member5244702025-10-012025-12-31in-capmkt:ReportableSegments3Member5244702025-12-31in-capmkt:ReportableSegments3Member5244702025-10-012025-12-31in-capmkt:ReportableSegments1Member5244702025-12-31in-capmkt:ReportableSegments1Member5244702025-10-012025-12-31in-capmkt:ReportableSegments2Member5244702025-12-31in-capmkt:ReportableSegments2Member5244702025-10-012025-12-31in-capmkt:ReportableSegments3Member5244702025-12-31in-capmkt:ReportableSegments3Member5244702025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15244702025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524470SYNCOMFNOTLISTEDINE312C01025SYNCOM FORMULATIONS (INDIA) LIMITEDMain BoardEquity2025-04-012026-03-312026-02-122026-02-04INRLakhsQuarterlyThird quarterMulti segment2026-02-1203:00:002026-02-1204:30:00Not applicable2025-10-012025-12-31UnauditedConsolidated1151406000550090001206415000474491000157108000-212320001745260002634000136000001544080009555350002508800000250880000599630001836000617990000189081000000018908100023618000212699000000094000000010.230.23000.230.230002025-04-012025-12-31UnauditedConsolidated3537597000167861000370545800015348840004668340007891000501378000779100040500000472424000303170200067375600041300067416900015460300069300001615330000512636000000051263600063444000576080000000094000000010.610.61000.610.61000Other Expenses154408000Other Expenses472424000PHARMACEUTICALS DRUGS AND FORMULATIONS1197496000TRADING OF COMMODITIES144000RENTING OF PROPERTY8775000PHARMACEUTICALS DRUGS AND FORMULATIONS3667289000TRADING OF COMMODITIES10600000RENTING OF PROPERTY275690001206415000370545800012064150003705458000PHARMACEUTICALS DRUGS AND FORMULATIONS245903000TRADING OF COMMODITIES37000RENTING OF PROPERTY7574000PHARMACEUTICALS DRUGS AND FORMULATIONS656021000TRADING OF COMMODITIES172000RENTING OF PROPERTY257670002535140006819600002634000779100000250880000674169000PHARMACEUTICALS DRUGS AND FORMULATIONS4548137000TRADING OF COMMODITIES17880000RENTING OF PROPERTY385387000495140400004951404000PHARMACEUTICALS DRUGS AND FORMULATIONS944814000TRADING OF COMMODITIES0RENTING OF PROPERTY919700095401100009540110001The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12022026 <BR> 2These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. <BR> 3The company is operating in 3 segments ie a Pharmaceuticals Drugs & Formulations b Trading of Commodities c Renting of Property, particulars of segment wise results are given as required <BR> 4As required under Regulation 33 of SEBI LODR Regulations 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 31st December 2025. The report does not have any impact on the above results and notes which needs explanation. <BR> 5Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. <BR> 6The Company currently have three Wholly Owned Subsidiaries namely Synmex Pharma Pvt Ltd Sante Biotech Pvt Ltd and Vincit Biotech International Pvt Ltd <BR> 7 The Government of India has notified four Labour Codes namely the Code on Wages 2019 the Industrial Relations Code 2020 the Code on Social Security 2020 and the Occupational Safety Health and Working Conditions Code 2020 with effect from 21 November 2025 which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes but the relevant rules are yet to be notified. Based on the available information as at reporting date no material liability is envisaged in this regard. Financial impact will be reviewed once the relevant rules are notified <BR> 8. Syncom has received an intimation regarding rejection of appeal and demand of Rs7089302 towards ineligible Input Tax Credit along with equivalent penalty under Sections 74 sub section 5 and 122 of the CGST Act 2017 total Rs14178604. The Company is obtaining legal advice and proposes to contest the matter by filing an appeal before the appropriate appellate authority.00Items that will be reclassified to profit and loss2361800023618000Items that will be reclassified to profit and loss6344400063444000002361800063444000